Clinical trial
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder…
NCT00478140 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00478140 |
|---|---|
| Title | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery |
| Official title | A Phase II Study Trastuzumab (NSC 688097) in Her2/Neu Positive Cancer of the Gallbladder or Biliary Tract (NCI 7756) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Malignant Neoplasm, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer |
| Intervention type | Biological, Other |
| Interventions | trastuzumab, laboratory biomarker analysis |
| Enrollment | 4 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2011 |
| Completion | Nov 1, 2011 |
| First posted | May 24, 2007 |
| Last update posted | Aug 20, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: